MétaCan
Menu
Back to cohort
Record W4410522616 · doi:10.1186/s12889-025-21953-8

Understanding the value of meningococcal vaccination for adolescents and young adults in the United States: insights from a steady-state modelling approach

2025· article· en· W4410522616 on OpenAlexaff
Edith Langevin, Corwin A. Robertson, Katherine Galarza, Ayşegül Doğu, Olivier Cristeau, E. Clay, Taeksoo Shin

Bibliographic record

VenueBMC Public Health · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBacterial Infections and Vaccines
Canadian institutionsSanofi (Canada)St. Thomas UniversityYork University
FundersSanofi
KeywordsMedicineVaccinationHerd immunityMeningococcal vaccineMeningococcal diseaseImmunizationPopulationBiostatisticsPediatricsPublic healthCost effectivenessVaccine efficacyNeisseria meningitidisDemographyIncidence (geometry)EpidemiologyEnvironmental healthImmunologyInternal medicine

Abstract

fetched live from OpenAlex

BACKGROUND: A two-dose series of quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended for the prevention of invasive meningococcal disease (IMD) in adolescents in the United States. In June 2024, the Advisory Committee on Immunization Practices discussed plans to review the adolescent meningococcal vaccination schedule. Various options are under consideration, including removing the first dose of MenACWY at age 11-12 years. OBJECTIVES: We evaluated the public health impact and cost-effectiveness of administering one or two doses of MenACWY compared to a scenario with no vaccination. METHODS: We constructed an incidence-based population model to compare costs and quality-adjusted life years (QALYs) associated with different vaccination schedules in a cohort of 11-25 year-olds, from a societal perspective, over a lifetime analytic horizon for outcomes related to death and disabilities. The main analyses compared various scenarios of MenACWY (Q) and MenB schedules to no vaccination. Further scenarios examined the impact of alternative assumptions applied to the first and/or second dose of MenACWY. RESULTS: Compared to no vaccination, 2 doses of MenACWY and 2 doses of MenB vaccine was projected to reduce IMD cases by 277 per year, resulting in an incremental cost-effectiveness ratio (ICER) of $625,322/QALY. Administering 2 doses of MenACWY was projected to reduce the annual number of IMD cases by 275 at an ICER of $438,948/QALY, which increased to 631 at an ICER of $190,030/QALY when herd immunity was considered. Alternatively, if only 1 dose of MenACWY was administered, the reduction in cases would be 253 if administered at 11-12 years old and 125 if given at 16 years, with ICERs of $252,249 per QALY and $352,169/QALY, respectively. Assuming a 25% increase in vaccination coverage rate, one MenACWY dose at 16 years resulted in 156 cases avoided. CONCLUSIONS: The two doses of MenACWY that are currently recommended play a crucial role in reducing the burden of IMD and the first dose contributes significantly (≥ 90%) to this reduction. It is essential to take this finding into account when considering any updates to the adolescent meningococcal vaccination schedule in the United States.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.008
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: Simulation or modeling
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.050
Threshold uncertainty score0.100

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.008
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.081
GPT teacher head0.296
Teacher spread0.214 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBMC Public HealthSame topicBacterial Infections and VaccinesFrench-language works237,207